Management of pediatric papillary thyroid cancer
Hell J Nucl Med. 2023 May-Aug;26 Suppl:60-64.ABSTRACTPapillary thyroid carcinoma (PTC) originates from the follicular cell of the thyroid gland. PTC is a rare cancer and usually develops in pre-existing thyroid nodules, which are not common in children. PTC is often multifocal and bilateral. Low-risk subtypes such as classic PTC and follicular variant account for the majority of PTC, while high-risk histologic subtypes such as tall cell variant, diffuse sclerosing variant and poorly differentiated thyroid cancer occur more rarely in children. It is worth noting that the size of the thyroid in children is smaller compared t...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Kalliopi Pazaitou-Panayiotou Source Type: research

Radioiodine refractory differentiated thyroid cancer
Hell J Nucl Med. 2023 May-Aug;26 Suppl:65-68.ABSTRACTDifferentiated thyroid cancer is composed of papillary (85%), follicular (13%) with their subtypes and anaplastic (<2%) thyroid cancer, derived from follicular dedifferentiation. In the majority of cases (85%), treatment is succeeded with thyroxine suppression and radioiodine ablation. However, there is a small percentage of patients presenting with local recurrence or metastases during follow up. In such cases, reoperation and radioiodine treatment are the treatments of choice. 10% of the aforementioned patients appear resistance to radioiodine treatment and they are...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Maria Boudina Source Type: research

Ultrasound investigation and management of the thyroid nodule.Tirads classification.Patient's follow-up after thyroidectomy
Hell J Nucl Med. 2023 May-Aug;26 Suppl:69-82.ABSTRACTThyroid's ultrasound examination is the first and main imaging modality for the morphological investigation of the gland following clinical examination. It depicts both the number and texture of both palpable and non-palpable nodules.PMID:37658569 (Source: Hellenic Journal of Nuclear Medicine)
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Evangelos G Destanis Source Type: research

Recent advances in breast cancer treatment
Hell J Nucl Med. 2023 May-Aug;26 Suppl:83-84.ABSTRACTBreast cancer treatment is determined by the molecular subtype both in the early stage and the advanced disease. While there is clear benefit from adjuvant systemic treatment for patients with early-stage triple negative and HER2 positive breast cancer, it was unclear in the past which patient with luminal breast cancer needs adjuvant chemotherapy. As a result, we used to overtreat or undertreat patients. In the era of personalized treatment, genomic panels have become as or more important than the anatomic extent of disease to define prognosis in luminal breast cancer. ...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Sophia Levva Source Type: research

PET/CT: Role in staging, in follow-up and in the evaluation of disease recurrence in gynecologic cancer
Hell J Nucl Med. 2023 May-Aug;26 Suppl:85.ABSTRACT18F-FDG PET/CT may facilitate improved diagnosis and treatment in gynecological fields. This method provides pretreatment prognostic information concerning the aggressiveness of tumors which may contribute to optimizing and individualizing patient therapy. Although 18F-FDG PET/CT has a limited role for local staging of primary cancer, it has an important role in staging, as it aids particularly in identifying the involvement of lymph nodes and distant metastases throughout the whole body in a single examination in patients with advanced-stage disease and also in restaging a...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Evangelia Skoura Source Type: research